Team

James Huang

• James is an industry veteran with over 30 years of biotech experience. He is a successful entrepreneur and investor dedicated to investing in disruptive innovation and supporting entrepreneurs to build global companies that will transform the lives of patients around the world.
• He founded Panacea Venture to focus on investments in global innovative early and growth stage healthcare and life sciences companies.
• James was previously Managing Partner of Kleiner Perkins (KPCB) China and Managing Partner at Vivo Ventures.
• Before joining Vivo in 2007, James was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. He also held senior roles in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. (acquired by Johnson & Johnson).
• James is currently a director at Kindstar Globalgene Technology Inc. (9960.HK), Connect Biopharma Holdings Limited (Nasdaq: CNTB) and several private companies.
• James received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley.